In conclusion, the typical genomic features of BPDCN and pDC-AML now appear clearly distinct, with potential interest in diagnosis (MYC, MYB, ETV6, RB1 in BPDCN, RUNX1 in pDC-AML) but above all from a prognostic or therapeutic perspective. This evidence concerns the gene MYC and acute myeloid leukemia.